The Company reported a net loss of approximately $8.4 million, or $0.25 per share, for the three months ended September 30, 2024, compared to a net loss of approximately $11.3 million, or $0.48 per ...

SOL-1 expected to be fully randomized by YE 2024 with topline data expected in Q4 2025 Cash balance of $427.2M as of September 30, 2024, expected to fund operations into 2028 Ocular to host a Q3 2024 ...

The treatment is the first approved gene therapy for AADC deficiency, the FDA said. People with this rare disorder have ...

As an alternative, some doctors have been prescribing metformin—an oral diabetes drug—off-label for weight loss ... says ...

PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, today announced that the Company requested a post-complete letter clarification ...

Garner, MD, Medical Director at SimpleFixRx to review ... Medication produced by compounded pharmacies instead of the ...

" I’m honored to join Innate Pharma at such a pivotal moment in its evolution,”said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. “ We achieved notable regul ...

In today’s fast-paced world, where youthfulness and vitality are often equated with productivity and happiness, many people ...

As the FDA issues a new warning about aspiration across all GLP-1 weight loss drugs, doctor groups are giving new ...

This drug is the world’s first-ever CRISPR/Cas13 RNA-editing therapy ... binding pathway through the Cas13 RNA editor to knockdown VEGF-A mRNA.” Xin Zhang, MD, MSc, COO and CMO of HuidaGene, ...